# 1 Abstract

2 Purpose: To develop an evidence-based guideline for nurses and other health care

professionals involved in pre- and postsurgical care of women with vulvar cancer (VC) or
vulvar intraepithelial neoplasia (VIN).

5 Methods: This evidence-based guideline was developed according to six domains of the

6 methodological framework AGREE II. Literature research with focus on cancer care,

7 symptom management and self-management/counselling was conducted from April to

- 8 August 2013 in the databases CINAHL, Cochrane Library, PsycINFO, PubMed as well as in
- 9 14 international guideline databases. Interdisciplinary experts (n=14) were involved in the
- 10 development of the guideline from December 2013 to January 2014. This guideline is
- 11 currently tested in the WOMAN-PRO II RCT (Clinical Trial No: NCT=1986725).

12 **Results:** For the definition of recommendations, five guidelines, one meta-analysis, two

13 systematic reviews and two randomized controlled trials were included. In total, 24

- 14 recommendations were formulated to answer 22 clinical questions based on patients'
- 15 perspective and experts' opinion. Evidence ranged from 3.5 to 5 (3.5 = weak evidence and/or
- 16 clinical relevance, 5 = best evidence and/or clinical relevance). The recommendations were
- subsumed under different themes regarding physical, psychological and psychosocialaspects.

19 **Conclusions:** The clinical practice guideline developed in this study firstly provides

20 recommendations for symptom management issues focusing on self-management

21 interventions for women with VC or VIN. As an interdisciplinary guideline it should be used in

addition to the existing medical guideline in the German speaking context.

23 Keywords: Evidence-based guideline; vulvar cancer; vulvar intraepithelial neoplasia;

24 symptoms and distress; self-management; symptom-management

25 26

27

28

29

30

## 31 Introduction

32 An annual incidence of two to seven per 100,000 women has been reported for vulvar 33 neoplasms (VN) in the United States and Europe (Hampl et al., 2011). The term "vulvar 34 neoplasms" comprises vulvar intraepithelial neoplasia ("premalignant lesions", VIN) and 35 vulvar cancer (VC) (Sideri et al., 2005). One predisposing factor for VIN mostly seen in 36 younger patients is Human Papilloma Virus (HPV). VC is more widespread in elderly women 37 and its cause is almost unknown (Alkatout et al., 2015). It is the fourth most common 38 gynaecologic cancer comprising several histological types, with squamous cell carcinoma 39 being the most common category. The gold standard for treating VC and high-grade VIN is 40 surgery (Alkatout et al., 2015). After vulvar surgical therapy women often experience 41 symptoms and related distress. Symptoms may be categorized into three types: wound-42 related symptoms (e.g. swelling), psychosocial symptoms (e.g. tiredness) and difficulties in 43 daily life (e.g. during sitting) (Senn et al., 2013). Even minimal surgical treatment causes a 44 variety of symptoms and postsurgical complications (Baker-Glenn et al., 2011). Women's 45 symptom experience can vary depending on the FIGO stage (International Federation of 46 Gynaecology and Obstetrics [Belhadj et al., 2014]) as well as on the type of treatment and 47 may affect the perceived quality of life (Novackova et al., 2015).

48 Due to reduced hospital length of stay after vulvar surgical therapy, women's selfmanagement of challenging situations has become a high priority in order to prevent 49 50 negative outcomes (Humphreys et al., 2008). Self-management can be defined as tasks 51 undertaken by individuals to deal with medical, role and emotional management of their 52 health condition (McCorkle et al., 2011). The three types of symptoms (wound-related, 53 psychosocial and difficulties in daily life) can be allocated to the tasks of self-management. 54 To support self-management, verbal and written information provide a basis for educating 55 patients about their condition and care (Silva, 2011). Structured counselling, including identification of pre-surgical risks for complications and planning of post-surgical 56 57 interventions can lower patient morbidity (Senn et al., 2015). However, women report a lack 58 of pre- and postsurgical counselling (Jefferies and Clifford, 2011). They described receiving

59 limited information from health care professionals with regard to symptom management 60 (Senn et al., 2011). To achieve effective symptom management, it is essential to understand 61 the individual's symptom experience (Senn et al., 2011). According to Dodd et al. (2001), 62 symptom management may be understood as a dynamic process with the aim of preventing 63 negative outcomes. Given et al. (2004) developed a nurse-delivered intervention to reduce 64 the severity of physical and psychological symptoms in patients receiving chemotherapy. For 65 this purpose, standardized information and approaches to problem solving were used to 66 reduce symptom severity. To implement self-management interventions and to develop care 67 plans, a patient-provider partnership is important (McCorkle et al., 2011). As Allen (2003) 68 stated in her study, women with VC need high-quality information delivered in an appropriate 69 environment by a clinical nurse specialist as part of a multidisciplinary team.

The current guideline for diagnosis and management of VC proposes an integrative
approach to caring for women with VC, including a skilled nurse as a key factor for patient
management in coordination with medical treatment (Royal College of Obstetricians and
Gynaecologists [RCOG], 2014).

74 Offering support provided by skilled nurses during treatment is a first step to put into practice 75 guideline recommendations. Nurses and other health care providers need evidence-based 76 guidelines for symptom management in order to support women systematically and 77 comprehensively in their symptom management. It can be expected that evidence-based 78 guidelines promote positive treatment outcomes (Puhan et al., 2014). In this context the 79 German Society for Gynaecology and Obstetrics (DGGG) (Working Group of Gynaecological 80 Oncology, 2009) developed guidelines for the treatment of vulvar premalignant and 81 malignant lesions, targeting surgery, radio- and chemotherapy. However, there remains a 82 shortage of recommendations concerning symptom management. To our knowledge, a 83 guideline containing recommendations focusing on the most prevalent physical and 84 psychosocial symptoms in women with VIN and VC does not yet exist. Consequently, it is 85 difficult for nurses and other health care providers to support symptom management in a 86 systematic and comprehensive manner. In response to an absence of synthesized evidence,

we developed a guideline for health care professionals with a focus on the most prevalent
postsurgical symptoms described in a previous study (Senn et al., 2013). Professionals can
use this guideline in counselling for women with VC or VIN after surgical treatment.

90 Therefore, our main research question was: Which recommendations are appropriate to

91 support symptom self-management with regard to the most prevalent postsurgical

92 symptoms/problems in women with VIN and VC?

93 Based on results from Senn et al. (2013), which focused the most prevalent postsurgical

94 symptoms, the main research question was operationalized into 22 clinical questions shown

96

95

### [table 1: Clinical questions]

## 97 Methods

in table 1.

98 The development of this guideline is based on the six domains of AGREE II, an instrument 99 internationally acknowledged for (I) assessing quality of guidelines, (II) providing a 100 methodological strategy for the development of guidelines and (III) supporting authors with 101 regard to reporting information in guidelines (Brouwers et al., 2010). Domains 1 to 4 are 102 defined 'scope and purpose', 'stakeholder involvement', 'rigour of development' and 'clarity of 103 presentation'. The last two domains consist of 'applicability' and 'editorial independence'. 104 A nursing counselling concept was developed according to the PEPPA framework (Bryant-105 Lukosius and Dicenso, 2004), including a clinical pathway. According to the six domains of 106 AGREE II (Brouwers et al., 2010) we developed a draft of the guideline in December 2013. A 107 group of six experts, consisting of physicians, specialist nurses and nursing scientists, 108 assessed this draft. We incorporated the experts' comments in our guideline which is 109 currently tested in the WOMAN-PRO II randomized controlled trial (Clinical Trial No: 110 NCT01986725).

## 111 **Domain 1: Scope and Purpose**

The target population of the guideline includes women with VC or VIN and surgical treatment with a curative and not a palliative intention. Results of previous studies in patients with VC or VIN undergoing surgery have shown that patients suffer from a high number of postsurgical symptoms (Senn et al., 2011; Senn et al., 2013). Affected women mentioned on average 20 symptoms, comprising wound-related symptoms, psychosocial issues and activities of daily living (Senn et al., 2012). Based on these results, we determined the primary and secondary outcomes.

## 119 **Domain 2: Stakeholder Involvement**

In order to assess views and preferences of the target population, we conducted semistructured interviews with patients with VC or VIN and surgical treatment. These interviews focused on the experience of postsurgical symptoms and resulting constraints to which women are exposed. Furthermore, we assessed the women's needs and investigated which improvements they regard as necessary for their care. Target users of the guideline are advanced practice nurses. Therefore, a gynaecologic-oncology nurse was part of the group of four experts who formulated and rated the guideline's recommendations.

Moreover, physicians and other health care professionals focusing on care of this specific patient population may apply the guideline too. To assess the view of these stakeholders, experts from different areas (gynaecology, oncology, radiology, nursing science) were involved in the development of the counseling intervention as well as in the review of the

131 guideline.

## 132 Domain 3: Rigour of Development

Criteria for selecting evidence: To identify current guidelines and studies focusing on care for women with VC or VIN undergoing surgery, we conducted a literature review guided by the clinical questions shown in table 1. Inclusion criteria for guidelines were (1) description of the methodological approach, (2) at least partly designed for nursing, (3) publication date from 2003 to 2013, (4) guidelines focusing on symptoms due to an oncological disease and (5) English or German language. Exclusion criteria for guidelines were (1) thematic focus on palliative care and end-of-life care, (2) guidelines in terms of guidebooks and (3) guidelinesconcerning chronic oncological symptoms.

141 Inclusion criteria for studies were (1) studies focusing on oncological symptoms, (2)

142 randomized controlled trial, systematic review, meta-analysis, (3) publication date from 2003

to 2013 and (4) English language. Exclusion criteria for studies were focus on patients in a

144 palliative or end-of-life situation.

145 We searched the following guideline-specific databases: American Cancer Society, Working

146 Group Supportive Care in Oncology, Rehabilitation and Social Medicine of The German

147 Cancer Society, Association of the Scientific Medical Societies in Germany, BC Cancer

148 Agency, EONS, European Society for Medical Oncology, GIN, Multinational Association of

149 Supportive Care in Cancer, NCCN, National Guideline Clearinghouse, NICE, New Zealand

150 Guidelines Group, ONS and SIGN. To identify meta-analyses, systematic reviews or

151 randomized controlled trials we selected the databases CINAHL, Cochrane Library,

152 PsycINFO and PubMed. Furthermore, we also checked reference lists of all included studies

153 for additional literature.

154 Based on the 22 clinical questions (table 1) thematic focuses were given. The thematic

155 focuses comprised Advanced Practice Nursing, assessment, counseling, information, self-

156 management and symptom management. For each thematic focus we developed questions

157 according to PICO which supported the identification of relevant search terms. The search

term used for each thematic focus are shown in table 2.

159

## [table 2: search terms]

160 The search terms were adapted for each database. An example for a search string for the

161 database PubMed is as follows: ((("Advanced Practice Nursing"[Mesh]) OR "Nurse

162 Clinicians"[Mesh])) AND (((("Vulvar Neoplasms"[Mesh]) OR vulvar intraepithelial neoplasia)

163 OR "Genital Neoplasms, Female" [Mesh]) OR "Carcinoma in Situ" [Mesh]) Filters: Meta-

164 Analysis; Randomized Controlled Trial; Systematic Reviews; Publication date from

165 2003/01/01 to 2013/07/30; English.

One person conducted the research between April and August 2013. The flowcharts of theliterature search are shown in figure 1 and 2.

168

## [figure 1: Flowchart of literature search to identify guidelines]

## 169 [figure 2: Flowchart of literature search to identify studies]

170 Strengths and limitations of the body of evidence: Two authors independently assessed the 171 methodological quality of all included studies. Guidelines were evaluated using the DELBI 172 instrument for methodological guideline appraisal (Association of the Scientific Medical 173 Society in Germany and Agency for Quality in Medicine, 2008). Meta-analyses, systematic 174 reviews and randomized controlled trials were appraised according to the FIT Nursing Care 175 tool (Panfil and Ivanovic, 2011) which was developed according to the guidelines of the 176 Cochrane Collaboration (Higgins and Green, 2011) and GRADE (Puhan et al., 2014). As in 177 the Swiss/German speaking context the FIT Nursing Care tool is well known, it has been 178 chosen in order to enhance the transparency of our approach especially for our target users. 179 We formulated the recommendations on the basis of the identified literature. In a voting 180 procedure of four experts with clinical and scientific expertise, each recommendation has 181 been discussed with regard to available evidence, health benefits, side effects and risks. 182 Eight external experts reviewed the guideline. An update is planned for 2018.

183 Domain 4: Clarity of Presentation

For optimal visibility, the recommendations are presented in a blue box. A list of all
recommendations can be found in the front section of the guideline.

### 186 **Domain 5: Applicability**

187 In the methodological part of the guideline, we named facilitators and barriers possibly

188 having an impact on the application of the recommendations. Furthermore, structure criteria

- 189 (e.g. ensuring that a specialized nurse is available for counselling in patients with vulvar
- 190 neoplasms), process criteria (e.g. providing contact with other healthcare services involved in

- 191 caring and treatment) and outcome criteria (e.g. pain level) were determined (Donabedian,
- 192 2008).

## 193 **Domain 6: Editorial Independence**

- 194 The Federal Office of Public Health (Switzerland) and the University of Applied Sciences St.
- 195 Gallen (Switzerland), funded the guideline. All persons involved in developing the guideline
- 196 made their contribution within their institutional work. The members of the development
- 197 group had no competing interests to declare.

### 198 Results

- 199 To determine the recommendations, we included five guidelines, one meta-analysis, two
- 200 systematic reviews and two randomized controlled trials.

201 Table 3 shows the results of the methodological guideline appraisal.

- In figure 3 and figure 4, the results of the methodological appraisal of the remaining studiesare visible.
- 204 [table 3: Methodological guideline appraisal, DELBI]
- 205 [figure 3: Methodological appraisal of systematic reviews and meta-analyses]
- 206 [figure 4: Methodological appraisal of randomized controlled trials]
- 207 In the domain "methodological rigour of purpose" four of the included guidelines reached a
- percentage of 52% or more (Cruickshank M.E., 2011; Mitchell et al., 2007; Poage et al.,
- 209 2008; Scottish Intercollegiate Guidelines Network [SIGN], 2008). Only one guideline
- achieved 48 % but could nevertheless be included because of its clinical relevance (Sheldon
- et al., 2008). Three guidelines (Mitchell et al., 2007; Poage et al., 2008; Sheldon et al., 2008)
- achieved rather low scores in the domain "stakeholder involvement". Reasons were that they
- 213 missed to report or did not involve key stakeholders, especially patients in the guideline's
- development. Low scores in the domain "general applicability" (e.g. Cruickshank M.E., 2011;
- 215 Mitchell et al., 2007; Sheldon et al., 2008) can be explained by the fact that guidelines failed
- to report barriers and facilitators to implementation of the guideline as well as resource

217 implications for applying the guideline. Within the domain 8 "methodological rigour of 218 development when using existing guidelines" especially in three of the included studies 219 (Mitchell et al., 2007; Poage et al., 2008; Sheldon et al., 2008) there was a lack of description 220 how the search for already existing guidelines was conducted, if included guidelines were 221 critically appraised and how the content of the guideline has influenced the 222 recommendations. 223 With regard to the included studies the meta-analysis was of good methodological quality 224 except for the domain "description of selection process of included studies" (McNeely et al., 225 2011). Both systematic reviews had methodological weaknesses, e.g. in the domain 226 "literature research" or "assessment of included studies" (Luckett et al., 2009; Ridner et al., 227 2012). 228 The randomized controlled trials had adequate research questions, recruitment and equal 229 treatment but nevertheless the sample size was too small (Beatty et al., 2010; Thomas et al., 230 2012). 231 In total, it was possible to formulate 24 recommendations on the basis of 22 clinical 232 questions which were categorized into the following themes: symptom self-assessment, 233 surgical wound and vulva care, postsurgical pain, postsurgical tiredness, postsurgical urinary 234 symptoms, lymphedema, difficulties concerning sitting, wearing clothes and activities of daily 235 *living, uncertainty* and *body image.* The recommendations for symptom management in 236 women with VC or VIN and surgical treatment are visible in table 4. The source of evidence 237 and grades of recommendations are included. 238 239 [table 4: Recommendations, including time, source of evidence and grade of 240 recommendation] 241 242 The grades of recommendations range from 3.5 to 5(3.5 = weak evidence and /or clinical)243 relevance, 5 = best evidence and / or clinical relevance). For each recommendation the

literature source and the time are listed (table 3). Eleven recommendations were classified

244

as grade 4, three were classified as grade 3.5, 3.75 and 4.25, and two as grade 4.75 or 5.

For each recommendation a maximum of three external sources were identified.

## 247 Discussion

248 Within the framework of this study we developed an evidence-based guideline focusing for 249 the first time on symptom management in women with VC or VIN after surgical treatment. 250 The development was based on the methodological principles of AGREE II (Brouwers et al., 251 2010). As described in the domains of AGREE II, stakeholder involvement and the rigour of 252 development are essential parts of a guideline's development. Current approaches for 253 guidelines development recommend an even stronger focus on different sources of 254 knowledge (e.g. including quantitative and qualitative research, contextual information and 255 expert practical and experience knowledge). The consideration of different sources of 256 knowledge should strengthen the guideline's relevance, applicability and practicability for 257 target users (Lukersmith et al., 2016). Therefore, besides the inclusion of the current best 258 external evidence, we included patients, experts in gynaecologic oncology and gynaecologic-259 oncology nurses as target users in the guideline's development. Especially patient 260 engagement is strongly recommended before and during the guideline's development as well 261 as in the phase of dissemination and implementation (Armstrong et al., 2016). Thus semi-262 structured interviews were conducted with women with VC or VIN and surgical treatment. 263 The women's opinion has been incorporated in framing the clinical questions, conducting the 264 review and the development of the recommendations. It is important to bear in mind that 265 stakeholders, including patients and health care professionals, should not only be included in 266 the developmental phase but also informed about the presence of such guidelines. Studies 267 have shown that, especially in patients, the awareness of guidelines is low but they have a 268 wish to be informed in order to be supported when choosing between different treatment 269 options (Fearns et al., 2016). We try to enhance the dissemination of our guideline by making 270 it accessible online for free and providing institutions with information about the guideline. To 271 support the guideline's applicability in clinical practice, the recommendations have been

272 formulated in an easily accessible, patient-centered and comprehensive manner (Allen,

273 2003; National Institute for Health and Care Excellence [NICE], 2012).

## 274 Strengths and limitations

275 This guideline was developed according to stringent methodological principles, 276 systematically considering all six steps of the AGREE II guideline (Brouwers et al., 2010). 277 The available literature was rated independently by two persons using internationally 278 accepted checklists. However, the literature search was conducted by only one researcher, 279 due to limited resources. To define recommendations, we included five guidelines, one meta-280 analysis, two systematic reviews and two randomized controlled trials. As the literature 281 offered only a limited number of interventions supporting women in their management of VC 282 or VIN after surgical treatment, we extended our research on women with other 283 gynaecological tumours, e.g. breast cancer. Due to limited external evidence, seven 284 recommendations are based on expert opinions.

## 285 Conclusions

286 This clinical practice guideline for symptom management in women with vulvar neoplasms is 287 the first interdisciplinary guideline focusing on self-management. It should be used in addition 288 to the existing medical guideline developed by the DGGG (Working Group of Gynaecological 289 Oncology, 2009) and the new medical guideline of the NCCN (National Comprehensive 290 Cancer Network, 2016). Our guideline supports early detection and assessment of 291 postsurgical symptoms on predefined timeframes, the use of evidence-based symptom-292 relieving interventions and interdisciplinary decisions regarding therapy by systematically 293 involving the patient as well as the medical perspective. The application of this guideline 294 should be tailored to the individual patient's needs with regard to treatment history, risk 295 factors, comorbidities and lifestyle. By using the WOMAN-PRO symptom diary, women can 296 be actively involved in symptom management. Empowerment concerning their self-297 management can be strengthened.

298 The development of this guideline has been conducted systematically in cooperation with all

- 299 relevant stakeholders (NICE, 2012) and on the basis of currently available evidence
- 300 (Association of the Scientific Medical Society in Germany and Agency for Quality in
- 301 Medicine, 2008; Royal College of Obstetricians and Gynaecologists, 2014; Working Group of
- 302 Gynaecological Oncology, 2009). Further research is required to test the guideline's
- 303 effectiveness and feasibility in home care settings. Future guideline development should
- 304 consider also additional postsurgical symptoms as well as side effects of adjuvant therapies,
- 305 such as chemotherapies and radiotherapies, in women with VIN and VC.

#### 306 **Conflict of interest**

307 The authors declare no conflict of interest.

#### 308 References

- Alkatout, I., Schubert, M., Garbrecht, N., Weigel, M.T., Jonat, W., Mundhenke, C., Günther, 309 310 V., 2015. Vulvar cancer: epidemiology, clinical presentation, and management options. 311 International journal of women's health 7, 305–313. 10.2147/IJWH.S68979.
- 312 Allen, J., 2003. The clinical nurse specialist in gynaecological oncology—the role in vulval 313 cancer. Best Practice & Research Clinical Obstetrics & Gynaecology 17 (4), 591-607. 314 10.1016/S1521-6934(03)00041-5.

315 Armstrong, M.J., Rueda, J.-D., Gronseth, G.S., Daniel Mullins, C., 2016. Framework for 316 enhancing clinical practice guidelines through continuous patient engagement. Health 317 expectations : an international journal of public participation in health care and health

- 318 policy. 10.1111/hex.12467.
- 319 Association of the Scientific Medical Society in Germany and Agency for Quality in Medicine, 320 2008. Deutsches Instrument zur methodischen Leitlinien-Bewertung (DELBI): Fassung

321 2005/2006+Domäne 8 (2008).

- 322 Baker-Glenn, E.A., Park, B., Granger, L., Symonds, P., Mitchell, A.J., 2011. Desire for 323 psychological support in cancer patients with depression or distress: validation of a 324 simple help question. Psycho-oncology 20 (5), 525–531. 10.1002/pon.1759.
- 325 Beatty, L.J., Koczwara, B., Rice, J., Wade, T.D., 2010. A randomised controlled trial to 326 evaluate the effects of a self-help workbook intervention on distress, coping and quality of 327 life after breast cancer diagnosis. The Medical journal of Australia 193 (5 Suppl), S68-73.
- 328 Belhadj, H., Berek, J., Bermudez, A., Bhatla, N., Denny, L., Fujiwara, K., Hacker, N., Avall-
- 329 Lundqvist, E., Mutch, D., Odicino, F., Pecorelli, S., Prat, J., Quinn, M., Seoud, M.-F.,
- 330
- Shrivastava, S.K., 2014. FIGO staging for carcinoma of the vulva, cervix, and corpus
- 331 uteri. International journal of gynaecology and obstetrics: the official organ of the

- 332 International Federation of Gynaecology and Obstetrics 125 (2), 97–98.
- 333 10.1016/j.ijgo.2014.02.003.
- Brouwers, M.C., Kho, M.E., Browman, G.P., Burgers, J.S., Cluzeau, F., Feder, G., Fervers,
  B., Graham, I.D., Grimshaw, J., Hanna, S.E., Littlejohns, P., Makarski, J., Zitzelsberger,
- 336 L., 2010. AGREE II: advancing guideline development, reporting and evaluation in health
- 337 care. CMAJ : Canadian Medical Association journal = journal de l'Association medicale
- 338 canadienne 182 (18), E839-42. 10.1503/cmaj.090449.
- Bryant-Lukosius, D., Dicenso, A., 2004. A framework for the introduction and evaluation of
   advanced practice nursing roles. Journal of advanced nursing 48 (5), 530–540.
- 341 10.1111/j.1365-2648.2004.03235.x.
- 342 Cruickshank M.E., 2011. The Management of vulval Skin Disorders. Accessed 11 December343 2014, 23 pp.
- 344 Dodd, M., Janson, S., Facione, N., Faucett, J., Froelicher, E.S., Humphreys, J., Lee, K.,
- 345 Miaskowski, C., Puntillo, K., Rankin, S., Taylor, D., 2001. Advancing the science of 346 symptom management. Journal of advanced nursing 33 (5), 668–676.
- 347 Donabedian, A., 2008. An introduction to quality assurance in health care. Recording for the
  348 Blind & Dyslexic, Princeton, N.J.
- 349 Fearns, N., Kelly, J., Callaghan, M., Graham, K., Loudon, K., Harbour, R., Santesso, N.,
- 350 McFarlane, E., Thornton, J., Treweek, S., 2016. What do patients and the public know
- about clinical practice guidelines and what do they want from them? A qualitative study.
  BMC health services research 16 (1), 74. 10.1186/s12913-016-1319-4.
- 353 Given, C., Given, B., Rahbar, M., Jeon, S., McCorkle, R., Cimprich, B., Galecki, A., Kozachik,
- S., Brady, A., Fisher-Malloy, M.J., Courtney, K., Bowie, E., 2004. Effect of a cognitive
  behavioral intervention on reducing symptom severity during chemotherapy. Journal of
  clinical oncology : official journal of the American Society of Clinical Oncology 22 (3),
  507–516. 10.1200/JCO.2004.01.241.
- 358 2014. Guideline for Diagnosis and Management of Vulval Carcinoma.

https://www.rcog.org.uk/globalassets/documents/guidelines/vulvalcancerguideline.pdf.
Accessed 10 April 2015.

- Hampl, M., Huppertz, E., Schulz-Holstege, O., Kok, P., Schmitter, S., 2011. Economic
  burden of vulvar and vaginal intraepithelial neoplasia: Retrospective cost study at a
- 363 German dysplasia centre. BMC Infect Dis 11 (1), 73. 10.1186/1471-2334-11-73.
- Higgins, Julian P. T., Green, S., 2011. Cochrane Handbook for Systematic Reviews of
  Interventions, 2nd ed. Wiley, s.l., 672 pp.
- 366 Humphreys, J., Lee, K.A., Carrieri-Kohlmann V, 2008. Theory of Symptom Management, in:
- Liehr, P.R., Smith, M.J. (Eds.), Middle range theory for nursing, 2nd ed. Springer Pub.,
- 368 New York, pp. 145–158.

- 2009. Interdisziplinäre S2k-Leitlinie für die Diagnostik und Therapie des Vulvakarzinoms und
   seiner Vorstufen. Zuckschwerdt, München, 64 pp.
- Jefferies, H., Clifford, C., 2011. A literature review of the impact of a diagnosis of cancer of
  the vulva and surgical treatment. Journal of clinical nursing 20 (21-22), 3128–3142.

373 10.1111/j.1365-2702.2011.03728.x.

- Luckett, T., Butow, P.N., King, M.T., 2009. Improving patient outcomes through the routine
- use of patient-reported data in cancer clinics: future directions. Psycho-oncology 18 (11),
  1129–1138. 10.1002/pon.1545.
- Lukersmith, S., Hopman, K., Vine, K., Krahe, L., McColl, A., 2016. A new framing approach
  in guideline development to manage different sources of knowledge. Journal of
  evaluation in clinical practice. 10.1111/jep.12566.
- 380 McCorkle, R., Ercolano, E., Lazenby, M., Schulman-Green, D., Schilling, L.S., Lorig, K.,

381 Wagner, E.H., 2011. Self-management: Enabling and empowering patients living with 382 cancer as a chronic illness. CA: a cancer journal for clinicians 61 (1), 50–62.

- 383 10.3322/caac.20093.
- McNeely, M.L., Peddle, C.J., Yurick, J.L., Dayes, I.S., Mackey, J.R., 2011. Conservative and
  dietary interventions for cancer-related lymphedema. Cancer 117 (6), 1136–1148.
  10.1002/cncr.25513.
- Mitchell, S.A., Beck, S.L., Hood, L.E., Moore, K., Tanner, E.R., 2007. Putting evidence into
   practice: evidence-based interventions for fatigue during and following cancer and its
- treatment. Clinical journal of oncology nursing 11 (1), 99–113. 10.1188/07.CJON.99-113.
   National Institute for Health and Care Excellence, 2012. The Guidelines Manual: Developing
- 391 and Wording Guideline Recommendations. http://www.nice.org.uk/article/pmg6/chapter/9-
- 392 Developing-and-wording-guideline-recommendations. Accessed 5 January 2016.
- 393 Novackova, M., Halaska, M.J., Robova, H., Mala, I., Pluta, M., Chmel, R., Rob, L., 2015. A
- 394 prospective study in the evaluation of quality of life after vulvar cancer surgery.
- International journal of gynecological cancer 25 (1), 166–173.
- 396 10.1097/IGC.00000000000313.

397 Panfil, E.-M., Ivanovic, N., 2011. Methodenpapier FIT-Nursing Care. Accessed 21 April 2014.

- 398 Poage, E., Singer, M., Armer, J., Poundall, M., Shellabarger, M.J., 2008. Demystifying
- 399 lymphedema: development of the lymphedema putting evidence into practice card.
  400 Clinical journal of oncology nursing 12 (6), 951–964. 10.1188/08.CJON.951-964.
- 401 Puhan, M.A., Schünemann, H.J., Murad, M.H., Li, T., Brignardello-Petersen, R., Singh, J.A.,
- 402 Kessels, A.G., Guyatt, G.H., 2014. A GRADE Working Group approach for rating the
- 403 quality of treatment effect estimates from network meta-analysis. BMJ (Clinical research
- 404 ed.) 349, g5630. 10.1136/bmj.g5630.

- Ridner, S.H., Fu, M.R., Wanchai, A., Stewart, B.R., Armer, J.M., Cormier, J.N., 2012. Selfmanagement of lymphedema: a systematic review of the literature from 2004 to 2011.
  Nursing research 61 (4), 291–299. 10.1097/NNR.0b013e31824f82b2.
- 408 Scottish Intercollegiate Guidelines Network, 2008. Management of cervical cancer.: A
- 409 national clinical guideline. http://www.sign.ac.uk/guidelines/fulltext/99/. Accessed 11
  410 December 2014.
- 411 Senn, B., Eicher, M., Mueller, M.D., Hornung, R., Fink, D., Baessler, K., Hampl, M.,
- 412 Denhaerynck, K., Spirig, R., Engberg, S., 2013. A patient-reported outcome measure to
- 413 identify occurrence and distress of post-surgery symptoms of WOMen with vulvAr
- 414 Neoplasia (WOMAN-PRO) a cross sectional study. Gynecologic oncology 129 (1), 234–
- 415 240. 10.1016/j.ygyno.2012.12.038.
- 416 Senn, B., Gafner, D., Happ, M.B., Eicher, M., Mueller, M.D., Engberg, S., Spirig, R., 2011.
- 417 The unspoken disease: symptom experience in women with vulval neoplasia and surgical
- 418 treatment: a qualitative study. European journal of cancer care 20 (6), 747–758.
- 419 10.1111/j.1365-2354.2011.01267.x.
- 420 Senn, B., Kobleder, A., Raphaelis, S., Mueller, M.D., Kammermann, B., White, K., Eicher, M.,
- 421 2015. Prevention and Reduction of Complications in Women with Vulvar Cancer:
- 422 Development of an Algorithm for Safer Multidisciplinary Care. JCT 06 (10), 821–832.
  423 10.4236/jct.2015.610090.
- Senn, B., Mueller, M.D., Hasenburg, A., Blankenstein, T., Kammermann, B., Hartmann, A.,
  Donovan, H., Eicher, M., Spirig, R., Engberg, S., 2012. Development of a postsurgical
  patient-reported outcome instrument for women with vulvar neoplasia. Oncology nursing
  forum 39 (6), E489-98. 10.1188/12.ONF.E489-E498.
- Sheldon, L.K., Swanson, S., Dolce, A., Marsh, K., Summers, J., 2008. Putting evidence into
  practice: evidence-based interventions for anxiety. Clinical journal of oncology nursing 12
  (5), 789–797. 10.1188/08.CJON.789-797.
- 431 Sideri, M., Jones, Ronald, W., Wilkinson, Edward, J., Pretti, M., Heller, Debra, S., Scurry, J.,
- Haefner, H., Neill, S., 2005. Squamous Vulvar Intraepithelial Neoplasia: 2004 Modified
  Terminology. ISSVD Vulvar Oncology Subcommittee. The Journal of Reproductive
- 434 Medicine 50 (11), 807–810.
- Silva, D.d., 2011. Evidence: Helping people help themselves : a review of the evidence
  considering whether it is worthwhile to support self-management. The Health Foundation,
  London, 39 pp.
- 438 Thomas, M.L., Elliott, J.E., Rao, S.M., Fahey, K.F., Paul, S.M., Miaskowski, C., 2012. A

439 randomized, clinical trial of education or motivational-interviewing-based coaching

- 440 compared to usual care to improve cancer pain management. Oncology nursing forum 39
- 441 (1), 39–49. 10.1188/12.ONF.39-49.

442 2016. Vulvar Cancer: (Squamous Cell Carcinoma). NCCN.org.